Seaport Therapeutics, Inc.
No enriched coverage for $SPTX in the last 7 days.
No SEC Form 4 filings for $SPTX in the last 30 days.
See all $SPTX insider activity →Seaport Therapeutics reported Phase 1 data for GlyphAgo, showing 6.8x bioavailability increase and 10x lower variability vs. unmodified agomelatine. Phase 2a for GAD has started, with Phase 2/3 planned for 1H 2027. The data supports the Glyph platform and GAD program, but efficacy and safety data are needed for larger impact.
H.C. Wainwright reiterated a Buy rating and $50 price target for Seaport Therapeutics (SPTX) after the first patient was dosed in a Phase 2a trial for GlyphAgo. The stock is currently at $17.93, down 5.4% over the past week. The trial evaluates GlyphAgo in adults with generalized anxiety disorder and sleep disturbance. Seaport expects to report top-line data in early 2028. Analysts highlight the company's strong financial position and clinical-stage pipeline.
Seaport Therapeutics (SPTX) began a Phase 2a trial for GlyphAgo, an anxiety and sleep disorder drug, in Australia. The six-week trial tests two dose levels and aims to report data in early 2028. GlyphAgo showed increased bioavailability in a Phase 1 trial. PureTech Health (PRTC) noted Seaport as a portfolio company.
Recent SPTX coverage spans financial news, technology and market movers.
The data validates the Glyph platform and may lift the stock as investors reassess the GAD program outlook.
Analyst coverage upgrade and trial start suggest upside potential.
First‑patient dosing is a positive catalyst that may lift the stock modestly.
Strong Buy initiation may trigger buying interest in the clinical‑stage company.
Positive early‑stage data may boost investor confidence and support upcoming Phase 2b readout.
AlphAI scores every news story that mentions SPTX with an AI model for sentiment and relevance, and aggregates insider trades from Seaport Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Seaport Therapeutics reported Phase 1 data for GlyphAgo, showing 6.8x bioavailability increase and 10x lower variability vs. unmodified agomelatine. Phase 2a for GAD has started, with Phase 2/3 planned for 1H 2027. The data supports the Glyph platform and GAD program, but efficacy and safety data are needed for larger impact.
1 min readH.C. Wainwright reiterated a Buy rating and $50 price target for Seaport Therapeutics (SPTX) after the first patient was dosed in a Phase 2a trial for GlyphAgo. The stock is currently at $17.93, down 5.4% over the past week. The trial evaluates GlyphAgo in adults with generalized anxiety disorder and sleep disturbance. Seaport expects to report top-line data in early 2028. Analysts highlight the company's strong financial position and clinical-stage pipeline.
2 min readSeaport Therapeutics (SPTX) began a Phase 2a trial for GlyphAgo, an anxiety and sleep disorder drug, in Australia. The six-week trial tests two dose levels and aims to report data in early 2028. GlyphAgo showed increased bioavailability in a Phase 1 trial. PureTech Health (PRTC) noted Seaport as a portfolio company.
2 min readMizuho initiated coverage on Tower Semiconductor (TSEM) with an Outperform rating and $300 price target. Other initiations include Precigen (PGEN) with a Buy rating and $12 target, Seaport Therapeutics (SPTX) with a Strong Buy rating and $46 target, PDF Solutions (PDFS) with a Buy rating and $60 target, and CF Industries (CF) with an Outperform rating and $162 target.
2 min readSeaport Therapeutics (SPTX) reported positive Phase 1 trial results for GlyphAllo, showing no next-morning driving impairment in healthy volunteers. The trial met primary and secondary endpoints, with GlyphAllo well-tolerated. The company plans to submit results to the FDA and present further data. SPTX stock closed at $24.06, up 3.95% in pre-market trading.
2 min readUBS upgraded SolarEdge (SEDG) to Buy with a $42 target, citing FCC benefits. Wolfe upgraded DT Midstream (DTM) to Outperform with a $145 target. Piper upgraded Neogen (NEOG) to Overweight with a $14 target. UBS upgraded Argenx (ARGX) to Buy with a $1,400 target. National Bank upgraded Scotiabank (BNS) to Outperform with a C$142 target. JPMorgan and BofA downgraded Intuit (INTU) to Neutral with a $331 target. Truist downgraded Dick's Sporting (DKS) and Nike (NKE). Wells downgraded GoDaddy (GDDY).
2 min readFive biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD
3 min readSeaport Therapeutics (SPTX) debuted on NASDAQ in August 2026 with a $1.4B market cap, following a $260M IPO. Its GlyphAllo asset is in Phase 2b trials for MDD, with results expected in 1H 2027. Bristol Myers (BMY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Sanofi (SNY) are potential acquirers. SPTX has $427.26M in cash, a Q2 2026 net loss of $62.60M, and a runway into 2029.
2 min readSeaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Enrollment in Phase 2b BUOY-1 trial of GlyphAllo TM in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 Phase 1 d
6 min readHOMBACH ROBERT J. purchased 13,000 indirectly-held shares of Seaport Therapeutics, Inc. (SPTX) at $18.14 ($0.24M total) on 2026-06-22.
2 min read
